Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations
AML Hub11 Feb

Symposium | Implications for clinical practice: Managing AML with FLT3-ITD and -TKD mutations

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the symposium by Gail J. Roboz, Weill Cornell Medicine, New York, US, in which she discussed the management of patients with acute myeloid leukemia (AML) with FLT3-internal tandem duplication (ITD) and FLT3-tyrosine kinase domain (TKD) mutations in clinical practice.


Roboz reflected on whether 7+3 regimens are the most appropriate approach for older patients with FLT3-mutated AML, and reviewed considerations for using targeted FLT3 inhibitor therapies in combination with standard intensive chemotherapy. She then highlighted the importance of measurable residual disease (MRD) assessment in guiding treatment decisions before and after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the potential of triplet therapies for the treatment of patients with FLT3m AML.


This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.

Avsnitt(35)

Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A

Symposium | Understanding the differences between FLT3-ITD and -TKD mutations in AML: Q&A

The AML Hub held a virtual symposium on November 19, 2025, titled Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. The symposium ended with...

12 Feb 7min

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation fro...

19 Jan 20min

Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance

Symposium | FLT3 mutations in AML: Types, prevalence, and clinical significance

The AML Hub held a webinar on November 19, 2025, titled, “Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice.” Here, we share one of the prese...

14 Jan 16min

ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety

ASH 2025 | Pivekimab sunirine + Ven + Aza in unfit patients with ND CD123+ AML: Phase Ib/II efficacy and safety

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Gail Roboz, Weill Cornell Medicine, New Yo...

13 Jan 8min

ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML

ASH 2025 | PARADIGM: Azacitidine + venetoclax vs conventional induction in fit adults with ND AML

Following the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the AML Hub was pleased to speak with Amir Fathi, Massachusetts General Hospital...

18 Dec 20257min

Clinical research round-up: Current and emerging treatments for IDH1-mutated AML

Clinical research round-up: Current and emerging treatments for IDH1-mutated AML

The AML Hub was pleased to speak with Eytan Stein, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the latest data presented on current and emerging treatments for acute myelo...

6 Nov 20254min

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

Menin inhibitors in AML: Bridging the gap between trial data and clinical practice

The AML Hub was pleased to speak with Emma Searle, The Christie NHS Foundation Trust, Manchester, UK. We asked for her thoughts on the topic “Menin inhibitors in AML: Bridging the gap between trial da...

24 Okt 20257min

Populärt inom Utbildning

historiepodden-se
rss-bara-en-till-om-missbruk-medberoende-2
det-skaver
alska-oss
nu-blir-det-historia
harrisons-dramatiska-historia
johannes-hansen-podcast
rss-viktmedicinpodden
not-fanny-anymore
sektledare
rss-sjalsligt-avkladd
roda-vita-rosen
allt-du-velat-veta
i-vantan-pa-katastrofen
sa-in-i-sjalen
rss-max-tant-med-max-villman
rikatillsammans-om-privatekonomi-rikedom-i-livet
rss-basta-livet
psykologsnack
sektpodden